Supplementary Table S3 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

Melissa R. Junttila; Claire E. Repellin; Sumeet Salaniwal; Robert L. Warne; Younho Lee; Haelee Kim; Kyung Ah Seo; Youngyi Lee; Hong-ryul Jung; Jason Baik; Jae Hoon Chang; Gina Andreatta; Jason E. Long; Jessica D. Sun; Stephanie W. Ni; Liliana Soroceanu; Lidia C. Sambucetti; Akash Kumar Das; Brenda Chan; Padmini Narayanan; Ashley S. Pereira; Edna Chow Maneval; Pratik S. Multani; Rupal Patel; Matt Panuwat; Brian R. Blank; Chudi Ndubaku; F. Anthony Romero; Anneleen Daemen; Alexander I. Spira; Lori S. Friedman

doi:10.1158/0008-5472.31228779

Supplementary Table S3 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

2026 Open access

Read full text

Authors: Melissa R. Junttila, Claire E. Repellin, Sumeet Salaniwal, Robert L. Warne, Younho Lee, Haelee Kim, Kyung Ah Seo, Youngyi Lee, Hong-ryul Jung, Jason Baik, Jae Hoon Chang, Gina Andreatta

+19 more

Jason E. Long, Jessica D. Sun, Stephanie W. Ni, Liliana Soroceanu, Lidia C. Sambucetti, Akash Kumar Das, Brenda Chan, Padmini Narayanan, Ashley S. Pereira, Edna Chow Maneval, Pratik S. Multani, Rupal Patel, Matt Panuwat, Brian R. Blank, Chudi Ndubaku, F. Anthony Romero, Anneleen Daemen, Alexander I. Spira, Lori S. Friedman

DOI: 10.1158/0008-5472.31228779

Cited by: 0

Abstract

Table S3 shows the cellular Ba/F3 potencies for enozertinib and other EGFR inhibitors

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Cancer Genomics and Diagnostics

Publication details

Publication date: 2 February 2026